TearLab reported net revenues of $5.2 million in the third quarter, a 24% increase from $4.2 million in the third quarter of last year, according to a press release.Net loss totaled approximately $5.8 million, or $0.17 per share on a non-diluted basis,…
Anti-VEGF therapy for age-related macular degeneration has been a major breakthrough in the battle against vision loss. The pivotal MARINA and ANCHOR trials showed a mean increase of 7 to 11 visual acuity letters at 1 year, substantially maintained at 2 years, with monthly injections of ranibizumab. In clinical trial settings, optical coherence tomography-guided variable-dosing regimens achieved comparable results. In the VIEW trials, after three monthly loading doses, bimonthly administration of aflibercept produced similar improvement to monthly ranibizumab.However, both the HORIZON and SEVEN-UP studies, which observed over the long term (Read more...)
Deep anterior lamellar keratoplasty restored corrected distance vision in patients with post-LASIK keratectasia, despite a high prevalence of residual ametropia, according to a study.The retrospective study included 20 eyes of 18 patients who underwent…
Alimera Sciences reported $2.4 million in net revenue in the third quarter, a 211% increase from $760,000 in the third quarter of the previous year, according to a press release.The company attributed the increase to higher use of Iluvien (fluocinolone…
(MedPage Today) — HCV treatment will again make headlines at the AASLD meeting and MedPage Today drills down with special features on renal cell carcinoma and multiple myeloma the week of Nov. 10.
CHICAGO — At the American Academy of Ophthalmology meeting here, Helmut Sachs, MD, discusses his presentation, “Subretinal Implantation and Functional Results of the Alpha IMS Chip to Restore Vision in 26 Blind Retinitis Pigmentosa Patients.”